Approval · Notice of Compliance 28037 · 2022
CAPRELSA: Notice of Compliance 28037
Issued April 28, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28037
- Date
- April 28, 2022
- Company
- Sanofi Genzyme, A Division Of Sanofi-Aventis Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph Convert the Product Monograph to the 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAPRELSA | Not yet assigned | — |
Medicinal ingredients
- VANDETANIB 100 MG per TAB
- VANDETANIB 300 MG per TAB